Send us Feedback

Novo Nordisk A/S (NVO)
QUOTE AND NEWS
Novo Nordisk wins Europe OK for diabetes drug
MarketWatch  Jul 3 
Novo Nordisk said the European Commission has granted marketing authorisation for Victoza, or liraglutide, for the treatment of type 2 diabetes in adults. Novo Nordisk will launch Victoza in the UK, Germany and Denmark during the summer and in...
Novo Nordisk (NVO) NewsBite - NVO Upgraded By Goldman Sachs
Market Intelligence Center  Jul 1 
Novo Nordisk (NVO) was upgraded today by analysts at Goldman Sachs and the stock is now at $54.82, up $0.36 (0.66%) on volume of 240,047 shares traded. The analysts upped the stock to Buy from Neutral. Over the last 52 weeks the stock has ranged...
Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
StreetInsider.com  Jul 1 
Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
StreetInsider.com  Jun 30 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medarex+%28MEDX%29+Will+Receive+Milestone+Payment+from+Novartis+%28NVO%29+for+FDA+Approval+of+Ilaris/4762679.html for the full story.
Sanofi defends safety of Lantus insulin
MarketWatch  Jun 29 
Sanofi-Aventis early Monday defended the safety of its long-acting insulin product Lantus, asserting that clinical trials have not associated the product with cancer. The European medical journal Diabetologia over the weekend reportedly...
[$] Vodafone interest spurs Deutsche Telekom
Financial Times  Jun 29 
The prospect of consolidation in the UK mobile telecoms market lifted the European sector though many doubt the UK regulator will allow the deal
Biotech Stocks: Sanofi, Novo Nordisk lower on drug-safety worries
MarketWatch  Jun 26 
Drug stocks trade mixed as European drugmakers Sanofi-Aventis and Novo Nordisk A/S lose ground amid safety concerns about their respective insulin products.
Sanofi, Novo Nordisk lead drug stocks south
MarketWatch  Jun 26 
Transaction in Own Shares
Market Wire  Jun 22 
BAGSVAERD, DENMARK -- (Marketwire) -- 06/22/09 -- At Novo Nordisk's ordinary general meeting on 18 March 2009, it was decided to reduce the company's B share capital from DKK 526,512,800 to DKK 512,512,800 by cancellation of part of the company's
Novo Nordisk A/S: Transaction in Own Shares
Market Wire  Jun 22 
Novo Nordisk A/S -- Transaction in Own Shares
Market Wire  Jun 15 
BAGSVAERD, DENMARK -- (Marketwire) -- 06/15/09 -- Novo Nordisk A/S - Share repurchase programme On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no
Novo Nordisk Says Some Stolen Insulin Found at Medical Center
Bloomberg  Jun 13 
Novo Nordisk AS, the world’s biggest maker of insulin, said some of its Levemir insulin that was stolen four months ago was found this week at a Houston medical center.
Alios raises another $8M
FierceBiotech  Jun 11 
With the help of new investor SR One, the corporate venture fund of GlaxoSmithKline, Alios BioPharma has raised an additional $8 million to advance its preclinical programs toward proof-of-concept. This is in addition to $24 million the company...
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
See All
BULLS: REASONS TO BUY

 
0% agree
 
MAKER OF INSULIN

See All
BEARS: REASONS TO SELL
Bears: Reasons To Sell
Feeling Bearish? Be the first to explain why this would make a poor investment
See All (0)
more ▼EditWIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Novo Nordisk A/S (NVO):
 
NVO AT A GLANCE
 
 
 
 
 
 
 
 
Please install Flash Player to view this chart.



[edit] References

Retrieved from "http://www.wikinvest.com/stock/Novo_Nordisk_A/S_(NVO)"
 
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki